Full-Time
Posted on 8/13/2025
Develops FDA-cleared prescription digital therapeutics
$85k - $110k/yr
New York, NY, USA
Hybrid
Hybrid role; must be in-office at least 3 days/week.
| , |
Click Therapeutics creates prescription software to treat health conditions with digital therapeutics. Its products are software applications that can be used as medicines alone or with traditional treatments, designed to affect cognitive and neurobehavioral processes underlying diseases. They are developed and validated through randomized controlled trials and pursue FDA clearance to market them as class II medical devices. Revenue comes from physicians who prescribe the apps and payers who reimburse them, with real-world evidence used to refine and personalize the software. A notable collaboration with Boehringer Ingelheim aims to develop a $500 million prescription digital therapeutic for schizophrenia. The leadership includes CEO David B. Klein and C-suite officers, with a focus on bringing clinically validated digital health solutions to patients who have unmet medical needs.
Company Size
51-200
Company Stage
Series D
Total Funding
$211.6M
Headquarters
New York City, New York
Founded
2012
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
401(k) Company Match
Unlimited Paid Time Off
Flexible Work Arrangement
Stock Options
Performance Bonus
Fertility Treatment Support
Professional Development Budget
Commuter Benefits
The financing combines a $50M Series D investment by Boehringer Ingelheim with additional dedicated funding to support commercialization. As part of the agreement, Boehringer is transferring responsibility for commercializing CT-155 to Click Therapeutics.
Click Therapeutics closes USD 50m Series D led by Boehringer for prescription digital device. April 9, 2026 New York-based Click Therapeutics has closed a Series D round anchored by a USD 50 million strategic investment from Boehringer Ingelheim, alongside additional dedicated commercial funding, to support the commercialization of CT-155, an investigational prescription digital therapeutic device for the experiential negative symptoms of schizophrenia. The financing accompanies a structural shift in the CT-155 program: Boehringer Ingelheim is transferring full product responsibility - including commercial and marketing authorization rights - to Click. CT-155 was co-developed by the two companies and has not yet received regulatory clearance. Click said proceeds will be directed toward commercialization activities, contingent on US FDA clearance. The Series D follows a Series C strategic investment by Medidata and Dassault Systèmes in 2025, and a USD 52 million Series B in 2021 co-led by H.I.G. BioHealth Partners and Accelmed Partners. CT-155 received US FDA Breakthrough Device Designation in 2024. The completed Phase III CONVOKE trial (NCT05838625) - a randomized, double-blind, 16-week study evaluating CT-155 versus a digital control app as an adjunct to standard antipsychotic therapy - met its primary endpoint. Treatment with CT-155 produced a 6.8-point improvement in negative symptom severity on the CAINS-MAP scale at 16 weeks, compared with 4.2 points in the digital control arm, representing a 62% relative improvement (Cohen's D effect size of -0.36; p=0.0003). Adverse event rates were 8.3% for CT-155 versus 13.4% for the control arm, with no serious adverse events in either group. A follow-on ENSPIRUS study (NCT06791122), led by Boehringer Ingelheim, is generating real-world effectiveness data and remains active. Click's platform produces regulated prescription mobile applications designed to function as the active therapeutic agent rather than as adjunct monitoring tools. The company describes its approach as operating at the intersection of biology and technology, using AI-based adaptive delivery and patient-centric design to encode psychosocial and neurobehavioral intervention techniques at clinical-grade fidelity. The underlying scientific rationale draws on neuroplasticity research and the established efficacy of cognitive behavioral and motivational enhancement therapies, which the platform aims to deliver consistently and at scale. The company holds 63 granted patents and has previously secured US FDA authorization for CT-132, a prescription digital therapeutic for episodic migraine, and Rejoyn, co-developed with Otsuka Pharmaceuticals for adjunctive treatment of major depressive disorder symptoms. Click has also acquired assets from Better Therapeutics, expanding into cardiometabolic disease, and holds a collaboration with Indivior in substance use disorders. David Benshoof Klein, CEO and founder of Click Therapeutics, said the company has spent over a decade building its capabilities in digital therapeutics and is focused on bringing CT-155 to patients following FDA clearance. No information was available in the provided source material on Klein's prior institutional affiliations or whether the company's platform originated from university research. Your email address will not be published. Required fields are marked *
Click Therapeutics has received a $50 million Series D investment from Boehringer Ingelheim, along with additional commercial funding to support the launch of CT-155, an investigational digital therapeutic for treating experiential negative symptoms of schizophrenia in adults. Under the agreement, Boehringer is transferring full product responsibility and commercialisation rights for CT-155 to Click Therapeutics. The companies co-developed the therapy, which received FDA Breakthrough Device Designation in 2024. CT-155's Phase III CONVOKE study was the first pivotal trial to demonstrate statistically significant reduction in experiential negative symptoms of schizophrenia as an adjunct to standard antipsychotic treatment. The treatment showed a Cohen's D effect size of -0.36, reflecting a 6.8-point improvement in negative symptom severity at 16 weeks, representing a 62% relative improvement versus the control arm.
Ultrahuman's smart ring can now help predict and prevent migraines. The new 'PowerPlug' uses biomarkers like HRV and sleep to help users manage their migraine attacks. Ultrahuman is expanding the capabilities of its smart ring, announcing a partnership with Click Therapeutics to launch a Migraine 'PowerPlug'. The new software feature is designed to help the estimated one billion people globally who suffer from migraines. The feature integrates Click's FDA-authorized digital therapeutics to deliver personalized insights and preventive recommendations. The PowerPlug (which is what Ultrahuman calls its bolt-ons available via the app) will land in early 2026 following a pilot phase. The brand has also noted it will be available to users in all of its major markets, including the US, UK, EU, and India. Shedding more light on triggers. The Migraine PowerPlug doesn't just track when a migraine occurs; it also attempts to identify physiological precursors. By analyzing biomarkers captured via the Ultrahuman Ring Air - including heart rate variability (HRV), sleep quality, movement, and stress load - the system looks for deviations that may correlate with an individual's specific migraine triggers. It then provides 'guided behavioral interventions'. Instead of generic advice, users might receive tailored goals for hydration, sleep schedules, or movement to mitigate the risk of an attack. Wareable Ltd. is eager to see how this functions in practice, as migraine triggers are notoriously diverse and vary from person to person. While stress and sleep are undoubtedly factors, changes in hormones, diet, sensory stimuli, and environmental weather are also common triggers. Another win for women. This launch aligns with Ultrahuman's growing focus on women's health, following its acquisition of fertility tech company viO Health last August and its rich partnership with cycle-tracking platform Clue announced in September. Since hormonal fluctuations are a major migraine trigger for many women, the PowerPlug will likely layer this data on top of cycle tracking to provide a more holistic view of potential risk windows. Again, Wareable Ltd.'ll keep an eye on it to see how it develops following its full release. The wareable view. This is another significant exclusive feature for Ultrahuman, as it seeks to distance itself from Oura's shadow. It's also another example of a smart ring brand leading the way with actionable, preventive insights, something smartwatch makers are playing catch-up on. Instead, companies like Ultrahuman have had their finger on the pulse of the latest digital health trends in the last few years - be it circadian rhythm, air quality, stress analysis, or women's health. By partnering with Click Therapeutics - a company with actual FDA authorizations - the reliability is further bolstered. And even if this new feature can only successfully predict migraine onset for a fraction of users - or at least help users understand their triggers more - it further solidifies Ring Air's place as an essential medical companion, not just another tracker.
Frontiers Health is delighted to welcome Click Therapeutics as a Strategic Partner for Frontiers Health 2025.